Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Alphamab and Sanofi to Test Dual HER2 Combination; Sanofi Gains Option

publication date: Jun 9, 2020

Suzhou Alphamab Oncology will collaborate with Sanofi to test a combination of KN026, Alphamab's anti-HER2 bispecific mAb, together with Sanofi's Taxotere® (Docetaxel) in HER2+ breast cancer. Sanofi will have a period of exclusivity to negotiate in-licensing rights for KN026. KN026 is an anti-HER2 bispecific antibody that binds two non-overlapping epitopes of HER2 and leads to a dual HER2 signal blockade. Alphamab has begun several clinical trials of the candidate in China and the US, including a combination study with Taxotere. More details....

Stock Symbols: (HK: 9966) (EURONEXT: SAN; NSDQ: SNY)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital